UNSPSC 51182060: Nandrolone phenpropionate

This classification denotes a therapeutic androgen with the molecular formula C27H34O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KF7Z9K2T3W, chemically known as 19-nortestosterone, hydrocinnamate but more generally known as nandrolone phenpropionate, which bears US NIH Compound Identifier 4435. European Medicines Agency schedules Nandrolone phenpropionate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03385MIG.

UNSPSC 51182060 Nandrolone phenpropionate (Commodity) encompasses pharmaceutical products supplied through state and local cooperative purchasing vehicles to government healthcare facilities. State and local governments procure nandrolone phenpropionate and related generic pharmaceuticals primarily through multistate cooperative purchasing alliances that aggregate demand across participating jurisdictions and authorize distribution through established pharmaceutical wholesalers. Issuing bodies include state procurement offices administering cooperative purchasing programs, state health departments, and local healthcare agencies participating in cooperative agreements. The scope of work involves manufacturers supplying pharmaceuticals with specified National Drug Codes (NDC), SKUs, UPCs, and packaging configurations; all products must comply with current Good Manufacturing Practices (cGMP), the Drug Supply Chain Security Act (DSCSA), and FDA requirements, with expiration dates of at least one year from manufacture and a minimum six-month shelf life.

The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued a Request for Proposal on January 20, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products distributed across participating state and local government facilities, including Oregon. Proposals were due March 26, 2026, with a question cutoff of February 18, 2026; awarded vendors will be provided to authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC) by May 15, 2026, with contracts effective July 1, 2026. Vendors must maintain contractual relationships with at least two of the three authorized wholesalers, maintain comprehensive insurance coverage including $5 million commercial general liability per occurrence, submit pricing in flat price or net price formats (NF30, NF60, NF90) or WAC-minus structures, and accept a 3 percent administrative fee on all contract purchases. The contract term is two years for new responders with optional extensions at MMCAP's discretion, while incumbent amendments align with existing expiration dates through June 30, 2028. Evaluation weighting prioritizes price competitiveness (75 percent), with remaining points assigned to fixed pricing (10 percent), compliance with administrative data format requirements (5 percent), EDI capability (5 percent), and agreement to the 3 percent administrative fee (5 percent). No specific award value or budget range was disclosed.